Complete enrollment in the randomized trial of ANKTIVA in BCG naïve NMIBC patients
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 14 Jan 2026
- Due
- 30 Jun 2026
- Delivered
- 7 May 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“full enrollment anticipated by Q2 2026”
What we found
Evidence strength A What the grades mean
The company confirmed in a May 2026 filing that the pivotal BCG-naïve NMIBC trial had achieved full enrollment, ahead of the Q2 2026 deadline.
-
A ImmunityBio, Inc. 8-K filed 2026-05-07
“The full enrollment of our pivotal BCG-naïve NMIBC trial, with independent confirmation that no additional patients are required, supports our planned sBLA submission in 2026.” ✓ confirmed on the page
-
A ImmunityBio, Inc. 10-Q filed 2026-05-07
“ANKTIVA + BCGBCG-naïve NMIBCPhase 2BFully enrolled” ✓ confirmed on the page
Market reaction: the shares moved -4.0% against the S&P 500 over the three sessions around the disclosure (6 May 2026 to 11 May 2026). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Randomized trial of ANKTIVA in BCG naïve NMIBC patients
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you ImmunityBio, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2026-IBRX-002826 · Corrections policy